HeartSciences Statistics
Total Valuation
HeartSciences has a market cap or net worth of $20.02 million. The enterprise value is $23.99 million.
| Market Cap | 20.02M |
| Enterprise Value | 23.99M |
Important Dates
The last earnings date was Monday, September 14, 2026, after market close.
| Earnings Date | Sep 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
HeartSciences has 4.80 million shares outstanding. The number of shares has increased by 200.72% in one year.
| Current Share Class | 4.80M |
| Shares Outstanding | 4.80M |
| Shares Change (YoY) | +200.72% |
| Shares Change (QoQ) | +16.78% |
| Owned by Insiders (%) | 15.93% |
| Owned by Institutions (%) | 3.20% |
| Float | 3.62M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4,301.99 |
| Forward PS | 299.09 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 5,181.53 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.14
| Current Ratio | 0.14 |
| Quick Ratio | 0.01 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -11.78 |
Financial Efficiency
Return on equity (ROE) is -1,851.90% and return on invested capital (ROIC) is -167.82%.
| Return on Equity (ROE) | -1,851.90% |
| Return on Assets (ROA) | -116.44% |
| Return on Invested Capital (ROIC) | -167.82% |
| Return on Capital Employed (ROCE) | 499.92% |
| Weighted Average Cost of Capital (WACC) | 14.72% |
| Revenue Per Employee | $323 |
| Profits Per Employee | -$732,802 |
| Employee Count | 14 |
| Asset Turnover | 0.00 |
| Inventory Turnover | 0.00 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +24.85% in the last 52 weeks. The beta is 1.86, so HeartSciences's price volatility has been higher than the market average.
| Beta (5Y) | 1.86 |
| 52-Week Price Change | +24.85% |
| 50-Day Moving Average | 3.09 |
| 200-Day Moving Average | 2.65 |
| Relative Strength Index (RSI) | 56.38 |
| Average Volume (20 Days) | 154,830 |
Short Selling Information
The latest short interest is 39,859, so 0.83% of the outstanding shares have been sold short.
| Short Interest | 39,859 |
| Short Previous Month | 114,152 |
| Short % of Shares Out | 0.83% |
| Short % of Float | 1.10% |
| Short Ratio (days to cover) | 0.26 |
Income Statement
In the last 12 months, HeartSciences had revenue of $4,519 and -$10.26 million in losses. Loss per share was -$3.19.
| Revenue | 4,519 |
| Gross Profit | 2,751 |
| Operating Income | -9.48M |
| Pretax Income | -10.26M |
| Net Income | -10.26M |
| EBITDA | -9.45M |
| EBIT | -9.48M |
| Loss Per Share | -$3.19 |
Balance Sheet
The company has $29,906 in cash and $4.00 million in debt, with a net cash position of -$3.97 million or -$0.83 per share.
| Cash & Cash Equivalents | 29,906 |
| Total Debt | 4.00M |
| Net Cash | -3.97M |
| Net Cash Per Share | -$0.83 |
| Equity (Book Value) | -2.03M |
| Book Value Per Share | -0.52 |
| Working Capital | -4.82M |
Cash Flow
In the last 12 months, operating cash flow was -$6.79 million and capital expenditures -$3,554, giving a free cash flow of -$6.80 million.
| Operating Cash Flow | -6.79M |
| Capital Expenditures | -3,554 |
| Depreciation & Amortization | 27,012 |
| Net Borrowing | 2.42M |
| Free Cash Flow | -6.80M |
| FCF Per Share | -$1.42 |
Margins
| Gross Margin | 60.88% |
| Operating Margin | -209,733.08% |
| Pretax Margin | -227,024.23% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
HeartSciences does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -200.72% |
| Shareholder Yield | -200.72% |
| Earnings Yield | -52.77% |
| FCF Yield | -34.96% |
Analyst Forecast
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | 3,680.42% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on May 17, 2024. It was a reverse split with a ratio of 1:100.
| Last Split Date | May 17, 2024 |
| Split Type | Reverse |
| Split Ratio | 1:100 |
Scores
HeartSciences has an Altman Z-Score of -42.17 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -42.17 |
| Piotroski F-Score | 2 |